HER2 positive resectable esophagogastric adenocarcinoma
Conditions
Brief summary
Feasibility rate, defined as proportion of patients receiving the protocol treatment according to the planned schedule before surgery without occurrence of at least one dose-limiting toxicity (DLT)
Detailed description
Assessment of safety of the treatment as determined by the incidence, type, causality, frequency, timing and severity of adverse events using NCI CTCAE 5.0, Perioperative morbidity (Clavien-Dindo classification) and mortality, Pathological complete remission (pCR) rate by local assessment corresponding to the ypT0 ypN0 stage category, R0 resection rate
Interventions
Sponsors
Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Feasibility rate, defined as proportion of patients receiving the protocol treatment according to the planned schedule before surgery without occurrence of at least one dose-limiting toxicity (DLT) | — |
Secondary
| Measure | Time frame |
|---|---|
| Assessment of safety of the treatment as determined by the incidence, type, causality, frequency, timing and severity of adverse events using NCI CTCAE 5.0, Perioperative morbidity (Clavien-Dindo classification) and mortality, Pathological complete remission (pCR) rate by local assessment corresponding to the ypT0 ypN0 stage category, R0 resection rate | — |
Countries
Austria, Germany
Outcome results
None listed